Диссертация (1139917), страница 17
Текст из файла (страница 17)
Nicoletti, C. Nourry, C. McDonald,G. Nunez, JP. Hugot, JP. Borg, V. Ollendorff // J. Biol. Chem. – 2007. – № 282(20)– P.15197–207.144.Lee K-H. A novel aminosaccharide compound blocks immuneresponses by Toll-like receptors and nucleotide-binding domain, leucine-rich repeat136proteins / K-H. Lee, Y-J. Liu, A. Biswas, C. Ogawa, KS. Kobayashi // J Biol Chem.– 2011. – № 286(7) – P. 5727–35.145.Lefrancier P. Muramyl-peptides Pure /P. Lefrancier, E. Lederer //Appl.Chem. – 1987. – № 59(3) – P.
449–54.146.Li, X. Chemical conjugation of muramyl dipeptide and paclitaxel toexplore the combination of immunotherapy and chemotherapy for cancer / X. Li, J.Yu, S. Xu, N. Wang, H. Yang, Z. Yan, G. Cheng, G. Liu. // Glycoconj J. – 2008. –№ 25(5). – P. 415–25.147.Li J. Regulation of IL-8 and IL-1beta expression in Crohn’s diseaseassociated NOD2 /CARD15 mutations / J. Li, T. Moran, E. Swanson, C. Julian, J.Harris, DK. Bonen, M. Hedl, DL. Nicolae, C. Abraham, JH. Cho // Hum. Mol.Genet.
– 2004. – №13 (16) – P. 1715–25.148.Liu GZS-D. Solid-phase synthesis of muramyl dipeptide (MDP)derivatives using a multipin method / GZS-D. Liu, S-Q. Xia, Z-K. Ding // BioorgMed Chem. – 2000. – №10 – P. 1361–63.149.Lozano R. Global and regional mortality from 235 causes of death for20 age groups in 1990 and 2010: a systematic analysis for the Global Burden ofDisease Study 2010. // Lancet. – 2012. –№380(9859) –P.
2095–128150.Lynch T.J. Ipilimumab in combination with paclitaxel and carboplatinas first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from arandomized, double-blind, multicenter phase II study. / I. Bondarenko, A. Luft, P.Serwatowski, F. Barlesi, R. Chacko et al. // J.
Clin. Oncol – 2012 – № 30(17) – P.2046–54.151.MacDonald, TT. Recent developments in the immunology ofinflammatory bowel disease Scand / TT. MacDonald, G. Monteleone, SL. Pender //J. Immunol. – 2000. – № 51(1) – P. 2–9.152.Macdonald TT. Immunity, inflammation, and allergy in the gut / TT.Macdonald, G.
Monteleone // Science. – 2005. – № 307(5717) – P. 1920–5.137153.Mahvi D.A. Ctla-4 blockade plus adoptive T-cell transfer promotesoptimal melanoma immunity in mice. /J.V. Meyers, A.J. Tatar, A. Contreras, M.Suresh, G.E. Leverson et al.
// J. Immunother. – 2015 – № 38(2) – P. 54–61.154.Maio M. Five-year survival rates for treatment-naive patients withadvanced melanoma who received ipilimumab plus dacarbazine in a phase III trial /J.J. Grob, S. Aamdal, I. Bondarenko, C. Robert C, L. Thomas L. et al. / J. Clin.Oncol. – 2015 – №33(10) – P. 1191–6.155.Mangoni M.L. Host-defense peptides: from biology to therapeuticstrategies. // Cell.
Mol. Life. Sci. – 2011 – №68 (13) – P. 2157–9.156.Martinon F. The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation / F. Martinon, K. Hofmann, J.Tschopp // Curr. Biol. – 2001. – № 11(4) – P. 118–20.157.Merser, C. Total synthesis and adjuvant activity of bacterialpeptidoglycan derivatives / C.
Merser, P. Sinay, A. Adam // Biochem Biophys ResCommun. – 1975. – № 66(4). – Р. 1316–22.158.Merten HBR. A facile two-steps synthesis of N-acetylmuramic acid byselective functionalization of HO-3 of 2-acetoamido-2-deoxyglucose / HBR. Merten// Carbohydr. Res. – 1989. – № 191 – P. 144–49.159.Moriguchi MUK. Therapeutic Effects of LK 423, a Phthalimido-desmuramyldipeptide compound, on dextran sulfate sodium induced colitis inrodents through restoring their interleukin-10 producing capacity / MUK.Moriguchi, N. Norisada, C. Ochi, A. Stalc, U. Urleb, S. Murooka // Arzneim Forsch.– 1999 – № 49 – P.
184–92.160.Morisaki, I. Effective immunity to dental caries: enhancement ofsalivary anti-Streptococcus mutans antibody responses with oral adjuvants / I.Morisaki, SM. Michalek, CC. Harmon, M. Torii, S. Hamada, JR. McGhee// InfectImmun. – 1983. – № 40(2). – Р.
577–91.161.Nagai YAK. Structural specificity of synthetic peptide adjuvant forinduction of experimental allergic encephalomyelitis / YAK. Nagai, S. Kotani, Y.138Watanabe, T. Shimono, T. Shiba, S. Kusumoto // Cell. Immunol. –1989. – № 35 –P. 168–72.162.Netea, MG. Nucleotide-binding oligomerization domain-2 modulatesspecific TLR pathways for the induction of cytokine release / MG. Netea, G.Ferwerda, DJ. de Jong, T.
Jansen, L. Jacobs, M. Kramer, TH. Naber, JP. Drenth, SE.Girardin, BJ. Kullberg, GJ. Adema, JW. Van der Meer // J Immunol. – 2005. – №174(10). – Р. 6518–23.163.Netea MG. Trained immunity: a program of innate immune memory inhealth and disease / MG. Netea, LAB. Joosten, E. Latz E, et al.
// Science (New York,NY). – № 2016 – P.352(6284).164.Newick K. Chimeric antigen receptor T-cell therapy for solid tumors//Mol. Ther. Oncolytics –2016. – №3: P. 160165.Ochi CNN. Interleukin-10 inducing activity of LK 423, a Phthalimido-desmuramyldipeptide compound / CNN. Ochi, N. Norisada, M. Moriguchi, A. Stalc,U. Urleb, S. Murooka // Arzneim Forsch. – 1999. – № 49 – P. 72–79.166.Ogura Y. Nod2, a Nod1 /Apaf-1 family member that is restricted tomonocytes and activates NF-kappa B / Y. Ogura, N. Inohara, A.
Benito, FF. Chen,S. Yamaoka, G. Nunez // J. Biol. Chem. – 2001. – № 276(7) – P. 4812–8.167.Ogura Y. Genetic variation and activity of mouse Nod2, a susceptibilitygene for Crohn’s disease / Y. Ogura, L. Saab, FF. Chen, A. Benito, N. Inohara, G.Nunez // Genomics. –2003. – № 81(4) – P.
369–77.168.O’Reilly, T. Enhancement of the effectiveness of antimicrobial therapyby muramyl peptide immunomodulators / T. O’Reilly, O. Zak // Clin Infect Dis. –1992. –№ 14 (5). – Р. 1100–9.169.Pan Q. MDP-induced interleukin-1 beta processing requires Nod2 andCIAS1 /NALP3 /Q. Pan, J. Mathison, C. Fearns, VV. Kravchenko, J. Da SilvaCorreia, HM. Hoffman, KS. Kobayashi, J. Bertin, EP. Grant, AJ. Coyle, FS.Sutterwala, Y. Ogura, RA.
Flavell, RJ. Ulevitch // J. Leukoc. Biol. – 2007. – № 82(1)– P. 177–83.139170.Parant MDC. In vivo and in vitro stimulation of nonspecific immunityby the b-D-p-aminophenyl glycoside of N-acetylmuramyl-L-alanyl-D-isoglitamineand an oligomer prepared by cross-linking with glutaraldehyde / MDC. Parant, F.Audibert, F. Parant, L. Chedid, E.
Sache, P. Lefrancier, J. Choay, E. Lederer // J.Infect. Dis. – 1978 – №138. – P. 378–86.171.Parant MA. Immunostimulant activities of a lipophilic muramyldipeptide derivative and of desmuramyl peptidolipid analogs. MA. Parant, FMAudibert, LA Chedid et al // Infection and Immunity. – 1980 –№ 27(3) – P.826-831172.Parant M.
Stimulation of non-specific resistance to infections bysynthetic immunoregulatory agents / M, Parant, L. Chedid // Infection. –1984 – №12(3) – Р. 230–4.173.Parant, MA. Selective modulation of lipopolysaccharide-induced deathand cytokine production by various muramyl peptides / MA Parant, P. Pouillart, C.Le Contel, FJ Parant, LA Chedid, GM Bahr // Infect. Immun. – 1995. – № 63(1). –Р. 110–5.174.Pauleau AL.
Role of nod2 in the response of macrophages to toll-likereceptor agonists / AL. Pauleau, PJ. Murray // Mol. Cell. Biol. – 2003. – № 23(21)– P. 7531–9.175.Petnicki-Ocwieja T. Nod2 is required for the regulation of commensalmicrobiota in the intestine / T. Petnicki-Ocwieja, T. Hrncir, YJ. Liu, A. Biswas, T.Hudcovic, H.
Tlaskalova-Hogenova, KS. Kobayashi // Proc. Natl. Acad. Sci. U S A.– 2009. – № 106(37) – P. 15813–8.176.Pillet A.H. A programmed switch from IL-15- to IL-2-dependentactivation in human NK cells / F. Bugault, J. Thиze, L.A. Chakrabarti, T. Rose. // J.Immunol. – 2009 – № 182(10) – P. 62–77.177.Porter D.L. Chimeric antigen receptor-modified T cells in chroniclymphoid leukemia / B.L. Levine, M. Kalos, A. Bagg, C.H. June// N.Engl.
J. Med.2011. – №365(8) P –725–33.178.Pouillart, PR. Enhancement by muramyl peptides of the protectiveresponse of interferon-alpha/beta against encephalomyocarditis virus infection / PR140Pouillart, FM Audibert, LA. Chedid, PL Lefrancier, GM Bahr // Int JImmunopharmacol.
– 1996. – № 18(3). – Р. 183–92.179.Pule M.A. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals withneuroblastoma / B. Savoldo, G.D. Myers, C. Rossig, H.V. Russell, G. Dotti et al. //Natuew Med. – 2008 – №14(11) – P. 1264–70.180.Qin J.
A human gut microbial gene catalogue established bymetagenomic sequencing / R. Li, J. Raes et al. //Nature – 2010 – № 464 (7285) – P.59–65.181.Reck M. Ipilimumab in combination with paclitaxel and carboplatin asfirst-line therapy in extensive-disease-small-cell lung cancer: results from arandomized, double-blind, multicenter phase 2 trial.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
